Hangzhou Thinheal Pharma-tech Co,.Ltd

Hangzhou Thinheal Pharma-Tech Co., Ltd. was established in 2019. It is a biopharmaceutical company that combines independent R&D, production, sales and customized research and development and production of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience in the peptide industry. Thinheal has built a R&D center and a production base. The total production capacity of chemically synthesized peptides has now reached several tons, ranking at the forefront of the industry. The company has a complete and efficient peptide R&D, production and sales system, and provides a full range of peptide industrialization services, including peptide API R&D and production business, peptide customized R&D and production (CDMO) business, and beauty peptide research and development and production business. The company's revenue is mainly from peptide API business. Peptide API products mainly include more than 20 varieties such as semaglutide, tirzepatide, liraglutide, etc., among which semaglutide, tirzepatide and other varieties have completed the US FDA DMF filing. The CDMO business includes project-based entrusted research and development, entrusted production and sales. The main customers of the CDMO business are innovative drug companies and scientific research institutions, among which some pharmaceutical companies have cooperated with Thinheal since the product development stage and have established a solid cooperative relationship.